Technology | May 13, 2015

Abbott, GE Healthcare Partner to Identify Source of Atrial Fibrillation

Integrated system brings together real-time patient data for assisting in faster analysis of complex heart rhythm disorders

Abbott, GE, CardioLab, RhythmView, atrial fibrillation, source

GE's CardioLab is one half of the integrated system with Abbott that will provide patient-specific data on the heart's electrical activity in real time.


May 13, 2015 — Abbott and GE Healthcare announced an agreement that will bring real-time, patient-specific data about the heart's electrical activity to cardiac electrophysiology labs. The goal of the collaboration is to speed up the diagnosis of the sources of atrial fibrillation and other heart rhythm disorders.

The integration of electrogram signal data from GE's CardioLab electrophysiology recording system into Abbott's RhythmView mapping software will allow doctors to use instantaneous electrical data of a person's heart to identify the sources of atrial fibrillation. By providing patient-specific diagnostics based on each person's unique physiology, this integrated system transforms current treatment approaches, which primarily rely on a one-size-fits-all anatomical approach.

Abbott's mapping software, or rotor identification system, helps physicians identify and target the specific areas of a person's heart that are perpetuating atrial fibrillation, the most common heart rhythm disorder. Abbott entered the catheter-based electrophysiology market last year through the acquisition of Topera Inc.

GE Healthcare’s CardioLab helps simplify the electrophysiology practice and streamline the workflow in diagnosis and treatment of complex cardiac cases.

For more information: www.abbott.com


Related Content

News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
Subscribe Now